About iPS cell-derived cell transplantation

Update: Jun. 8, 2026

• Can patients who reside outside Japan receive treatment for Parkinson’s disease using iPS cell-derived cell transplantation in Japan?

  ボタン

  At this time, it is not possible to receive treatment for Parkinson's disease by iPS cell-derived cell transplantation as a self-pay medical service.

  In addition, we will not conduct any international joint clinical trials. We have not considered accepting patients residing outside Japan for treatment in Japan, nor do we have any plans to consider this in the future.

• Can patients residing outside Japan participate in clinical trials for Parkinson’s disease by iPS cell-derived cell transplantation in Japan?

  ボタン

  Patients residing outside Japan are not eligible to participate in clinical trials for Parkinson's disease by iPS cell-derived cell transplantation conducted in Japan.

  Our U.S. subsidiary is currently conducting a clinical trial in the United States involving iPS Cell–derived cell transplantation for Parkinson’s disease. For further inquiries, please contact through this inquiry form.

  For further inquiries, please contact through this inquiry form.
  Contact Sumitomo Pharma America (SMPA) | Sumitomo Pharma America, Inc.

  For details regarding the clinical trial, please refer to the information provided on this website.
  Search ClinicalTrials.gov for: Parkinson Disease, Recruiting studies, Sponsor/Collaborator: Sumitomo Pharma America, Inc. | Card Results | ClinicalTrials.gov